Methods for characterizing and purifying VEGF-receptor fusion proteins
AT529126A2Pending Publication Date: 2026-08-15REGENERON PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- AT2026095006
- Authority / Receiving Office
- AT · AT
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-12-19
- Filing Date
- 2024-12-19
- Publication Date
- 2026-08-15
Abstract
Anti-VEGF proteins, including the VEGF trap protein aflibercept, can be manufactured to have a low content of an aspartyl protease (e.g., a low content of cathepsin D), for example, less than 1 ppm of the aspartyl protease.
Need to check novelty before this filing date? Find Prior Art